Two binding targets, different jobs
Bispecific antibodies recognize two targets. Some bring T cells into contact with cancer cells, while others block two signaling pathways. Ivonescimab combines PD-1 and VEGF targeting; cadonilimab targets PD-1 and CTLA-4. These are different from CD3-engaging antibodies used in some blood cancers.
“Bispecific” describes design, not a single indication or a universal superiority over single-target antibodies. An antibody can also carry a payload, creating a bispecific ADC.
| Design | Clinical question |
|---|---|
| T-cell engager | Can immune cells be brought into contact with the cancer? |
| Dual checkpoint | Does blocking two immune brakes add enough benefit to justify toxicity? |
| Immune–vascular | Can modifying blood-vessel signaling improve immune treatment? |
Match the mechanism to the diagnosis
Selection depends on cancer subtype, the specific target, previous treatment and the approved setting. A hematology patient may be comparing a readily available antibody with a manufactured CAR-T product; a lung cancer patient may be comparing immune-based regimens. These are different decisions, with different evidence and practical constraints.
A ready-made antibody and a manufactured cell product
An antibody usually avoids an individual manufacturing wait, but it may require repeated treatment and prolonged infection prevention. CAR-T involves collection and manufacturing followed by a different recovery pathway. Availability, treatment duration and evidence for the exact disease all matter; convenience alone does not establish superiority.
Source [6]
Global treatment frontiers
A key question is whether engaging a second pathway improves on established PD-1 therapy. HARMONi-2 directly compared the PD-1 × VEGF antibody ivonescimab with pembrolizumab in first-line PD-L1-positive advanced NSCLC; the 2026 survival update extends the earlier progression-free-survival evidence. China has already approved the corresponding monotherapy setting, making this more than a laboratory concept.
A separate approach combines PD-1 and CTLA-4 blockade in cadonilimab. Following Chinese approvals in gastric and cervical cancer, the global COMPASSION-37 trial began enrolling in 2026 to compare gastric-cancer regimens incorporating cadonilimab, nivolumab or chemotherapy. An ongoing head-to-head program is an important next step, not yet a result.
Blood-cancer development is also moving earlier: in March 2026, the FDA approved teclistamab with daratumumab after at least one prior myeloma line containing a proteasome inhibitor and an immunomodulatory agent. This is a specific combination indication, not permission to use every CD3 bispecific at the same stage.
Treatment and observation
Some T-cell-engaging products use step-up dosing and enhanced early monitoring to manage immune activation. Other bispecifics are administered on a repeated infusion schedule, sometimes with chemotherapy. The exact product determines admission needs, premedication, dosing schedule and whether a caregiver must stay nearby.
The first doses and later doses are different phases
For a T-cell engager, a step-up schedule introduces treatment while the team watches for cytokine release and neurologic symptoms. Later visits still require infection and blood-count review. A long interruption can alter restart requirements, so do not treat a missed dose like an ordinary missed appointment.
Source [6]
Do not generalize the safety profile
Cytokine release syndrome and neurologic toxicity matter for some T-cell-engaging antibodies. Immune checkpoint blockade can inflame normal organs. VEGF blockade can add hypertension, proteinuria, bleeding and wound-healing concerns. The combination of mechanisms determines what must be checked before treatment and what symptoms need urgent review.
Know which risk comes from which mechanism
- CD3 engagement: ask about fever, confusion, infection prevention and immunoglobulin monitoring.
- Checkpoint blockade: carry a list of immune-related warning symptoms even after the infusion course ends.
- VEGF blockade: disclose bleeding, poorly controlled blood pressure and planned surgery.
Estimated total treatment cost
Costs differ substantially between solid-tumor antibody treatments and T-cell-engaging treatment for blood cancers. The ranges below apply to the named medicines and treatment settings.
| Treatment plan | Estimated total cost |
|---|---|
| Ivonescimab — selected solid-tumor treatment plans | US$13,000–58,000 |
| Cadonilimab — selected solid-tumor treatment plans | US$13,000–60,000 |
| Blinatumomab — initial 1–2 cycles | US$58,000–158,000 |
What’s included
These are estimates of total medical treatment costs for the listed treatment plans. In addition to the named medicines, they include specialist consultations and assessment, pretreatment tests, routine laboratory and imaging follow-up as needed, treatment administration and nursing where applicable, necessary hospitalization and monitoring, and routine supportive care. Travel and accommodation are not included.
Your individual treatment costs
Many ongoing antibody treatments do not have a fixed treatment duration, and costs accumulate with the treatments received. Blinatumomab is given in defined cycles; the range above covers initial treatment, not all later cycles or a subsequent transplant. Other bispecific antibodies require their own estimate. This range is indicative only; your individual costs may fall outside it. Contact us for a personalized cost estimate based on your medical needs and specialist assessment.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.